Analysts Issue Forecasts for OPKO Health FY2027 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Equities researchers at Zacks Research issued their FY2027 earnings estimates for shares of OPKO Health in a report issued on Thursday, March 20th. Zacks Research analyst R. Department anticipates that the biotechnology company will post earnings per share of ($0.09) for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

OPK has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, March 19th. Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Wednesday, March 12th. Finally, StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.81 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm has a 50-day moving average of $1.66 and a 200-day moving average of $1.57. OPKO Health has a one year low of $0.92 and a one year high of $2.04. The company has a market cap of $1.22 billion, a P/E ratio of -9.53 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.

Institutional Trading of OPKO Health

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rubric Capital Management LP grew its stake in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after purchasing an additional 4,284,336 shares during the last quarter. Millennium Management LLC boosted its stake in shares of OPKO Health by 85.3% during the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC raised its stake in OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after buying an additional 1,502,342 shares in the last quarter. Altshuler Shaham Ltd bought a new stake in OPKO Health during the 4th quarter valued at approximately $2,082,000. Finally, Norges Bank purchased a new position in shares of OPKO Health during the 4th quarter worth approximately $1,657,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average cost of $1.48 per share, for a total transaction of $740,000.00. Following the completion of the transaction, the chief executive officer now owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. This trade represents a 0.24 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired a total of 964,971 shares of company stock valued at $1,493,692 over the last three months. 47.26% of the stock is currently owned by insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.